Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (69): sc-65765

AChRα1 Antibody (69) is a rat monoclonal IgG2a antibody that detects AChRα1 in bovine samples through applications such as western blotting (WB) and immunofluorescence (IF). AChRα1, also known by various aliases including ACHRD, CHRNA, CMS2A, FCCMS, SCCMS, or CHRNA1, is a crucial component of the nicotinic acetylcholine receptor family, which plays a vital role in neurotransmission. This 482 amino acid multi-pass membrane protein is essential for muscle contraction and synaptic transmission, as AChRα1 forms a transmembrane aqueous pore that allows ions to flow in response to acetylcholine binding. Notably, AChRα1 exists in two alternatively spliced isoforms, with isoform 1 being specifically expressed in skeletal muscle, while isoform 2 is widely distributed across various tissues, including the brain, heart, kidney, liver, lung, and thymus. The presence of these isoforms suggests diverse functional roles in different physiological contexts, particularly in muscle and neuronal signaling. AChRα1′s ability to undergo conformational changes upon neurotransmitter binding is critical for function, as these changes directly influence synaptic activity and muscle contraction. Anti-AChRα1 antibody (69) is an invaluable tool for researchers studying the dynamics of neurotransmission and the physiological implications of acetylcholine signaling in bovine models.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (69) References:

1. Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man.  |  Garchon, HJ. 2003. J Autoimmun. 21: 105-10. PMID: 12935778
2. Analysis and mapping of CACNB4, CHRNA1, KCNJ3, SCN2A and SPG4, physiological candidate genes for porcine congenital progressive ataxia and spastic paresis.  |  Genini, S., et al. 2007. J Anim Breed Genet. 124: 269-76. PMID: 17868079
3. In pursuit of the high-resolution structure of nicotinic acetylcholine receptors.  |  Chen, L. 2010. J Physiol. 588: 557-64. PMID: 19995851
4. Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1.  |  Calabrò, M., et al. 2016. Neuropsychobiology. 74: 159-168. PMID: 28494468
5. Genetic basis and phenotypic features of congenital myasthenic syndromes.  |  Engel, AG. 2018. Handb Clin Neurol. 148: 565-589. PMID: 29478601
6. Slow Channel Syndrome Revisited: 40 Years Clinical Follow-Up and Genetic Characterization of Two Cases.  |  Boon, HTM., et al. 2022. J Neuromuscul Dis. 9: 525-532. PMID: 35466948
7. Pregnancy outcomes in patients with congenital myasthenic syndromes.  |  O'Connell, K., et al. 2022. Muscle Nerve. 66: 345-348. PMID: 35661384
8. Molecular and Physiological Functions of PACAP in Sweat Secretion.  |  Yamashita, M., et al. 2023. Int J Mol Sci. 24: PMID: 36902003
9. 'Untargeting' autoantibodies using genome editing, a proof-of-concept study.  |  Keppeke, GD., et al. 2023. Clin Immunol. 251: 109343. PMID: 37094742
10. A dinucleotide repeat and a Hae III polymorphism in the human nicotinic acetylcholine receptor alpha-subunit gene (CHRNA1).  |  Djabiri, F., et al. 1997. Clin Genet. 52: 130-2. PMID: 9298750

The preferred Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 antibody is Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (153): sc-65829.